{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008507","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.631544+00:00","generated_at":"2026-06-25T22:26:56.743340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxcyte Q1 net loss $39M, cash $352M; VAX-24 topline results due end-2022","bullets":["Q1 net loss $39.0M vs $21.2M YoY; R&D $31.7M, G&A $7.5M.","Cash, cash equivalents and investments $352.3M at March 31, 2022, including $107.6M net from public offering.","VAX-24 Phase 1/2 study dosing in both phases; topline safety, tolerability, immunogenicity results expected by year-end 2022.","Separate VAX-24 Phase 2 study in adults 65+ expected to start mid-2022; topline results expected H1 2023.","Appointed Mikhail Eydelman as SVP, General Counsel & Corporate Secretary in April 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008507","json":"https://secwatch.observer/filing/0000950170-22-008507.json","markdown":"https://secwatch.observer/filing/0000950170-22-008507.md","text":"https://secwatch.observer/filing/0000950170-22-008507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000095017022008507/0000950170-22-008507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000095017022008507/pcvx-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:26:56.743340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}